Biopharmaceutical company developing targeted protein degradation therapies for cancers and other diseases.
Arvinas, Inc., a dynamic clinical-stage biotechnology firm, specializes in the discovery, development, and commercialization of innovative therapies aimed at degrading disease-causing proteins. The company is at the forefront of engineering proteolysis targeting chimeras (PROTAC), a cutting-edge technology that leverages the body's natural protein disposal mechanisms to degrade and eliminate harmful proteins associated with various diseases.
At the core of Arvinas' pipeline are groundbreaking candidates like Bavdegalutamide and ARV-766. These investigational PROTAC protein degraders are designed for oral administration and are currently undergoing Phase 1/2 clinical trials. They hold promise for treating men with metastatic castration-resistant prostate cancer by selectively targeting disease-specific proteins for degradation.
Additionally, Arvinas is advancing ARV-471, another orally bioavailable PROTAC targeted protein degrader. This innovative therapy is undergoing Phase 3 clinical trials for the treatment of patients with locally advanced or metastatic estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast cancer, reflecting the company's commitment to addressing critical unmet medical needs.
Arvinas, Inc. has established strategic collaborations with leading pharmaceutical entities such as Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. These partnerships underscore Arvinas' dedication to leveraging collective expertise and resources in advancing its pioneering PROTAC technology towards potential commercialization. Founded in 2013 and headquartered in New Haven, Connecticut, Arvinas continues to redefine therapeutic possibilities through its innovative approach to protein degradation.